Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Residual dizziness after BPPV repositioning: vestibular rehabilitation vs betahistine vs no treatment
ChiCTR1800017328Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of betahistine in benign paroxysmal positional vertigo (BPPV) (3 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Vestibular activities and participation at 12 weeks, Computerized dynamic posturography at 12 weeks and 1 more. Started Aug 2018; status: recruiting.
02
Drugs
betahistine
03
Conditions
benign paroxysmal positional vertigo (BPPV)
Beyond the preview
Go deeper on ChiCTR1800017328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017328.